A pharmaceutical industry leader with extensive accomplishments in marketing strategy, field force effectiveness, and team development. A track record of advancing diverse brands in a challenging environment, optimizing critical business processes, and building competitive advantage. • Creates consistent growth in top-line sales and market share through times of challenge and change for brands. Achieves profitability and growth through focus on efficiency and a rigorous approach to customer insight and customer value. • Builds a highly skilled and driven sales force by optimizing core training and rewards systems for both sales reps and sales managers. • Draws on extensive scientific and clinical understanding, derived from doctorate and post-doctorate training, clinical practice, and research experience. • Develops high-performance teams by advancing a dynamic of innovation, accountability, and positive competition; strengthening employee engagement; and creating an urgent sense of mission. • Impactful communicator across a diversity of contexts, including business presentations to global peers, communication to customers, and media interactions. Influences and negotiates effectively through strategic preparation, as well as sensitivity to cultural and personality diversity. Builds alliances and synergies with internal customers. • A results-focused performance coach who draws out aspirations, identifies obstacles to progress, and creates pragmatic development plans. Focuses clear-headedly on the individual report’s short-term departmental objectives and long-term leadership potential. • Balances playful creativity with rigorous business analysis and integration of best practices.

Vice-President, Product Strategy (Canada) @ • Led the design and implementation of marketing strategy, local life-cycle team management, and staff engagement and development for Rituxan, Herceptin, Avastin, Perjeta, Kadcyla, Actemra, Esbriet, Zelboraf, Erivedge, Cathflo, Xeloda, and Tarceva. • Led launch of Gazyva, Cotellic, Atezolizumab, Alectinib, Lebrikizumab, Ocrelizumab and the subcutaneous formulation Rituxan. • Active in the Canadian Leadership Team executive committee of Roche Canada. Key participant in the Commercial Committee reporting to the President and CEO. • Led movement toward, focus on and measurement of patient centricity in marketing: positioning patients at the centre of everything we do. From July 2015 to Present (6 months) Toronto, Canada AreaVice-President, Sales and Marketing, Oncology (Canada) @ • Led the design and implementation of marketing strategy, sales promotion, local life-cycle team management, and staff engagement and development for Rituxan, Herceptin, Avastin, Xeloda, and Tarceva. • Led launch of Zelboraf, Erivedge, Perjeta, Kadcyla, Gazyva and the subcutaneous formulation Rituxan. • Active in the Canadian Leadership Team executive committee of Roche Canada. Key participant in the Commercial Committee reporting to the President and CEO. • Led movement toward, focus on and measurement of customer value and satisfaction. As a result, customer satisfaction scores improved year-over-year, and the Rituxan business unit became market leader in hematology in Canada. • Active in a wide range of critical organizational activities. Participated in the Pension committee, helped design the career development criteria and paths for sales and marketing, and led the electronic social media taskforce. From August 2011 to July 2015 (4 years) Toronto, Canada AreaBusiness Unit Director, Hematology @ • Realized consistent year-over-year growth of sales, profitability and market share from 2006 through 2011. • Achieved multiple and diverse launches, and drove early and aggressive adoption in key indications compared to performance in Western Europe. • Led movement toward, focus on and measurement of customer value and satisfaction. As a result, customer satisfaction scores improved year-over-year, and the Rituxan business unit became market leader in hematology in Canada. • Introduced a field force effectiveness initiative that correlated sales results, customer satisfaction outcomes, and rep improvement on an individual basis. Based on success to date, the initiative is being adopted throughout the wider company. • Successfully led the Canadian business team in negotiations with Health Canada for priority approvals, and led the Canadian business team in listing agreement negotiations with several provincial decision makers. • Initiated measurement of employee engagement within the business unit. Translated results into a comprehensive employee engagement program that resulted in significant improvement in engagement. • Represented the Canadian Affiliate on an array of International Business Teams. From November 2006 to August 2011 (4 years 10 months) Toronto, Canada AreaMarketing Director, Hematology @ From January 2006 to November 2006 (11 months) Toronto, Canada AreaAssociate Medical Director, Hematology & Oncology @ • Effectively developed and managed key opinion leaders, including National Cancer Institute of Canada. • Led the design and implementation of local phase III and IV studies to support data generation and physician experience in alignment with brand strategy. From April 2003 to January 2006 (2 years 10 months) Toronto, Canada AreaMarketing and Sales Manager, Virology @ • Led Canadian marketing activities necessary to successfully prepare for launch of Fuzeon, including negotiations with Health Canada, PMPRB, and private and public payers. • Managed day-to-day activities of HIV national sales force. Provided sales force direction and coaching to support Invirase and Fortovase sales in a highly competitive marketplace. • Developed and conducted engaging and productive marketing advisory boards with Canadian KOLs. • Created effective marketing materials and sales tools for HIV sales force in a restrictive regulatory environment. From January 2001 to April 2003 (2 years 4 months) Toronto, Canada AreaAssociate Medical Director, Infectious Diseases @ • Effectively developed and managed Canadian opinion leaders in support of the Rocephin, Invirase and Pegasys brands. • Led the design and implementation of local phase III and IV studies to support data generation and physician experience in alignment with brand strategy. From October 1998 to December 2001 (3 years 3 months) Toronto, Canada AreaSenior Associate @ • Consulted to several pharmaceutical companies in the areas of product development and marketing, clinical research and data analysis. • Phase 4 Health was later acquired by McKesson SPS From January 1997 to October 1998 (1 year 10 months) Toronto, Canada AreaVice Chair, Ethics Review Committee @ • Managed operations and administration of a board of healthcare professionals and laypersons involved in the review of pharmaceutical research protocols for ethical and scientific validity. From January 1996 to January 1998 (2 years 1 month) Toronto, Canada AreaClinical Instructor, Doctor of Pharmacy Program @ • Practiced as a clinical pharmacist in St. Michael’s Hospital Intensive Care Units, lectured with the University of Toronto’s Doctor of Pharmacy program, and supervised graduate students during their clinical training. From January 1995 to January 1997 (2 years 1 month) Toronto, Canada AreaClinical Pharmacy Specialist, Trauma and Neurosurgical Intensive Care Unit @ • Practiced as a clinical pharmacist in St. Michael’s Hospital Intensive Care Units, lectured with the University of Toronto’s Doctor of Pharmacy program, and supervised graduate students during their clinical training. From May 1995 to December 1996 (1 year 8 months) Research Fellow, Dept of Pharmacy Practice, & Clinical Associate, Program in Emergency Medicine @ • Practiced as a clinical pharmacist in the Emergency Departments and Intensive Care Units of three inner-city Chicago hospitals, participating in several ongoing clinical research studies, and teaching undergraduate pharmacy and medical students. From 1993 to 1995 (2 years) Greater Chicago AreaPharmacy Practice Resident, Detroit Receiving Hospital @ • Practiced as a clinical pharmacist in the Detroit Receiving Hospital, supporting multidisciplinary care teams and teaching undergraduate pharmacy and medical students. From 1992 to 1993 (1 year) Greater Detroit Area

Executive Program @ Queen's University From 2008 to 2008 Pharma Marketing Champions Program, Marketing @ INSEAD From 2002 to 2002 Doctor of Pharmacy, Pharmacy @ Wayne State University From 1990 to 1992 Bachelor of Pharmacy, Pharmacy @ Wayne State University From 1988 to 1990 Bachelor of Science, Pharmacology and Toxicology @ The University of Western Ontario From 1985 to 1988 Brian Jahns is skilled in: Pharmaceuticals, Biopharmaceuticals, Monoclonal Antibodies, Pharmaceutical Sales, Healthcare Marketing, Oncology, Hematology, Virology, Pharmaceutics, Health Care Marketing, Biotechnology, Hospital Sales, Immunology, Commercialization, Therapeutic Areas